anti-CD33/anti-CD123 bispecific nanobody T cell engager (Sanofi)

N/A

Report date: 2025/03/14 16:41:32

Base Information

Drug Nameanti-CD33/anti-CD123 bispecific nanobody T cell engager (Sanofi)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionMyeloid cell surface antigen CD33 modulatorsInterleukin-3 receptor subunit alpha modulators

TargetsMyeloid cell surface antigen CD33Interleukin-3 receptor subunit alpha

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumFrance

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSanofi

China Registration ClassN/A

Develop Information

Active CompaniesSanofi

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A